Create a Free Profile
Tell us about you: what you’re living with, what you’ve tried and what you’re exploring.
Next-Generation Small-Molecule Inhibitors (RAS and Menin Inhibitors) When Your Cancer Has a Known Mutation
Targeted medicines that switch off the specific genetic drivers of some cancers, often taken as a pill. Find the practices offering them and choose the ones you want.
Approved for Some Uses
Several RAS and menin inhibitors are FDA-approved for cancers with specific genetic changes. Newer inhibitors that reach more mutations are investigational.
Free to join. No card required.
What Are RAS and Menin Inhibitors?
RAS genes act like a switch that tells cells to grow. When one is mutated, the switch can stick in the on position and drive cancer. For decades RAS was considered impossible to target. RAS inhibitors now block certain mutated forms of it, and newer ones are designed to reach many more.
Menin inhibitors work in certain acute leukemias, where a protein called menin helps keep leukemia cells growing. Blocking it can allow those cells to mature normally. Both kinds of medicine work only when the cancer carries the specific genetic change they target.
Conditions It’s Used or Studied For
Lung Cancer with a KRAS Mutation
Colorectal Cancer
Pancreatic Cancer (In Trials)
Acute Myeloid Leukemia
Acute Leukemias with KMT2A or NPM1 Changes
Only your physician can say whether it is right for you.
Before You Match
What to Know
-
Your Tumor’s Genetics Decide
These medicines only work against specific mutations, so tumor or blood testing comes first. Ask whether yours has been tested.
-
Some Are Approved, Some Are Not
Approved inhibitors cover certain mutations. Medicines for other RAS mutations, and for cancers like pancreatic cancer, are mostly in trials.
-
Pills Still Need Monitoring
Even oral therapy comes with regular visits and lab work. Menin inhibitors carry a specific risk, called differentiation syndrome, that teams watch for.
-
Combinations Are Common
Many are given alongside other medicines. Ask what the full treatment plan would include.
More About RAS and Menin Inhibitors
Health e Match summarized this information from the sources listed below. It is general information, not medical advice.
Who Is a Candidate?
These medicines work only on cancers with a specific genetic change. KRAS G12C inhibitors are approved for certain non-small cell lung cancers after earlier treatment, and, combined with an antibody, for certain colorectal cancers. Menin inhibitors are approved for acute leukemias with a KMT2A rearrangement or an NPM1 mutation that has come back or not responded to treatment.
Testing your tumor or blood for these changes comes first. Medicines aimed at other RAS mutations, including in pancreatic cancer, are being studied in trials.
What to Expect
Most of these medicines are pills taken daily at home. Before you start, your team confirms the target mutation with tissue or blood testing.
Menin inhibitors may be started with closer monitoring, sometimes in the hospital, because of a specific early side effect described below.
Recovery and Follow-Up
Expect regular visits with blood tests to check blood counts and liver function, and periodic heart rhythm tests (EKGs) for some of these medicines. Scans or bone marrow tests show how the cancer is responding, typically every couple of months.
Risks and Side Effects
KRAS inhibitors commonly cause diarrhea, nausea, tiredness and changes in liver tests. Some can affect heart rhythm.
Menin inhibitors can cause differentiation syndrome, in which leukemia cells mature quickly and trigger fever, breathing difficulty, swelling or low blood pressure. It needs prompt treatment, so your team will tell you exactly what symptoms to report. They can also affect heart rhythm.
Cost and Insurance
Oral cancer medicines are often covered under a pharmacy benefit, which can mean high copays. Prior authorization is common. Manufacturer copay programs and independent foundations can help; ask your practice to check for you before your first fill.
Choosing a Practice
Questions worth asking in your first conversation:
- Has my cancer been tested for KRAS, NPM1 or KMT2A changes, and can you order testing if not?
- Which approved inhibitors fit my mutation and history?
- Are there trials for mutations not covered by approved medicines?
- How will side effects be monitored, especially in the first weeks?
Alternatives to Consider
Depending on the cancer, alternatives include chemotherapy, immunotherapy, other targeted therapies, and for acute leukemia, intensive chemotherapy, venetoclax-based combinations and stem cell transplant. Your oncologist can explain how a targeted inhibitor compares.
Sources
Find a Practice That Offers It
Searching for RAS and menin inhibitors usually means a long list of names and no way to tell who actually offers it. Here, you meet verified practices that treat what you listed, and you decide who to talk to.
We’ll Introduce You
We only introduce verified practices that treat what you listed.
Choose Each Other
Swipe on the ones you like. When they swipe back — it’s a match!
Free to join. No card required.
Questions
What Patients Ask
Are RAS inhibitors FDA-approved?
Yes, for specific uses. Inhibitors of the KRAS G12C mutation are approved for certain lung and colorectal cancers. Inhibitors aimed at other RAS mutations are investigational.
Are menin inhibitors FDA-approved?
Yes. Menin inhibitors are approved for certain acute leukemias with KMT2A or NPM1 changes, typically when the leukemia has come back or not responded to other treatment.
How do I know if I have a RAS mutation?
Through genetic testing of your tumor or blood, often called biomarker or molecular testing. Your oncologist can tell you whether it has been done.
What should I list on my profile?
Your diagnosis, any mutation you know about, treatments you have had, and that you are exploring targeted therapy.
Start Matching Today
Build a free profile in minutes. List what you’re living with and that you’re exploring RAS and menin inhibitors, and meet the practices that treat it.
Free to join. No card required.
This page is general information, not medical advice, and it was last updated October 15, 2026. healthematch.com makes introductions between patients and practices in the United States. It does not provide medical care, does not enroll anyone in clinical research, and does not recommend any particular procedure or provider. Where a practice has documented a therapy’s regulatory status, it is shown exactly as documented. Are you a practice? See the RAS and menin inhibitors page for practices.